<code id='9223706431'></code><style id='9223706431'></style>
      • <acronym id='9223706431'></acronym>
      <center id='9223706431'><center id='9223706431'><tfoot id='9223706431'></tfoot></center><abbr id='9223706431'><dir id='9223706431'><tfoot id='9223706431'></tfoot><noframes id='9223706431'>
      • <optgroup id='9223706431'><strike id='9223706431'><sup id='9223706431'></sup></strike><code id='9223706431'></code></optgroup>
        5. <b id='9223706431'><label id='9223706431'><select id='9223706431'><dt id='9223706431'><span id='9223706431'></span></dt></select></label></b><u id='9223706431'></u>
          <i id='9223706431'><strike id='9223706431'><tt id='9223706431'><pre id='9223706431'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-30 03:36:13 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：6862
                                  
                                    
          
                                   
          Editor’s note: A recording of the event is embedded below.
          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
          advertisement
          Featured Speakers
          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Why Novartis is going to walk from its acquisition of MorphoSys
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles